on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics: Review and Outlook as of September 2026
GenSight Biologics shared an update on its activities for September 2026. The biopharmaceutical company, focused on gene therapies for neurological diseases, confirmed the successful transfer of its manufacturing process for LUMEVOQ® to Catalent. This transfer ensures reproducible yields for future production.
Clinically, all patients for the REVISE study have been identified and the last treatment is scheduled for December 2026. Compassionate access programs in France have resumed and several patients have already been treated.
Financially, the revenues related to the AAC program were collected in early September. GenSight will publish its half-year results on September 29. The silence period will begin on September 15, 2026.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news